Oxford, UK – 27 January 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces a change to the Group’s Board of Directors.
Dr. Siyamak (“Sam”) Rasty has informed the Board that he will not be standing for re-election at the Company’s AGM in June 2023. Sam joined the Board in December 2020 and is a member of the Scientific and Technology Advisory Committee and was a member of the Audit Committee until December 2021.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: “It has been a pleasure to have Dr. Sam Rasty on the Board. His extensive experience in biopharma R&D and in building and growing successful gene therapy companies has been a valuable asset to Oxford Biomedica. As we focus on our innovation-led CDMO business, I would like to express my thanks for his service to the Company, in particular his contribution to our work in externalising our therapeutics business, which is progressing well, and wish him well for the future.”
Dr. Sam Rasty, Non-Executive Director of Oxford Biomedica added: “I am honoured to have had the opportunity to serve on the Board of Oxford Biomedica and assist the Company as it has grown to become a world leader in viral vectors. I wish the team continued success in the future as Oxford Biomedica focuses on becoming a world-class, innovation-led CDMO.”
Oxford Biomedica plc:
Stuart Paynter, Chief Financial Officer – T: +44 (0)1865 783 000
Taylor Boyd, VP, Head of IR – T: +1 (984) 268 8488 / E: email@example.com
Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 7394 562 425 / E: firstname.lastname@example.org
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: email@example.com
Mary-Jane Elliott / Matthew Cole / Angela Gray
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Further information is available at www.oxb.com.